Cargando…

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

Background: Expression of programmed death ligand (PD-L1/B7-H1/CD274) represents a mechanism of immune escape for renal cell carcinoma (RCC) cells. Drugs blocking PD-L1 or its receptor are in clinical development and early data suggests that tumor PD-L1 expression may predict response. Patients and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jilaveanu, L.B., Shuch, B., Zito, C. R., Parisi, F., Barr, M., Kluger, Y., Chen, L., Kluger, H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931264/ https://www.ncbi.nlm.nih.gov/pubmed/24563671 http://dx.doi.org/10.7150/jca.8167

Ejemplares similares

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
por: Baine, Marina K., et al.
Publicado: (2015)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
por: Tran, Thuy T., et al.
Publicado: (2019)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

Clear Cell Renal Cell Carcinoma Metastasized to the Ampulla of Vater 16 Years after Nephrectomy—A Rare Case
por: Lu, Jun, et al.
Publicado: (2022)

Impact of Laparoscopic Partial Nephrectomy and Open Partial Nephrectomy on Outcomes of Clear Cell Renal Cell Carcinoma
por: Yu, Feng, et al.
Publicado: (2021)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
por: Lu, Benjamin Y, et al.
Publicado: (2021)

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
por: Zito, Christopher R., et al.
Publicado: (2012)

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2022)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Heart Metastases of Clear Cell Renal Cell Carcinoma
por: Romejko, Katarzyna, et al.
Publicado: (2023)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Solitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
por: Antoniou, Nikolaos, et al.
Publicado: (2004)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Trisacryl Gelatin Microembolism and Metastases in the Lung after Renal Artery Embolization and Nephrectomy for Renal Cell Carcinoma
por: Borja Alvarez, Andres, et al.
Publicado: (2015)

Systemic Immunotherapy for the Treatment of Brain Metastases
por: Cohen, Justine V., et al.
Publicado: (2016)

Retroperitoneal drop metastases following robotic partial nephrectomy for renal cell carcinoma
por: Elgendi, Kareem, et al.
Publicado: (2023)

Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear‐cell renal cell carcinoma
por: Okazaki, Akihito, et al.
Publicado: (2020)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

AB090. Establishment of prediction model of progression after radical nephrectomy or partial nephrectomy for Chinese patients with clear cell renal cell carcinoma
por: Zhao, Yao-Rui, et al.
Publicado: (2015)

The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases
por: Zhao, Zhijian, et al.
Publicado: (2019)

Multiple metastases of renal clear cell carcinoma to the organs of the head
por: Sawicki, Piotr, et al.
Publicado: (2014)

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
por: Oria, Victor O., et al.
Publicado: (2022)

A unique presentation of a renal clear cell carcinoma with atypical metastases
por: Staderini, F., et al.
Publicado: (2015)

Successful partial nephrectomy of a T1b multilocular clear cell renal cell carcinoma arising in a renal graft
por: Elec, Florin Ioan, et al.
Publicado: (2018)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

Spontaneous Regression of Delayed Pulmonary and Mediastinal Metastases from Clear Cell Renal Cell Carcinoma
por: Shields, Lisa B.E., et al.
Publicado: (2020)

Editorial Comment to Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear‐cell renal cell carcinoma
por: Ohba, Kojiro
Publicado: (2021)

Bladder metastasis with additional metastases in multiple other organs 4 years after radical nephrectomy for clear cell renal cell carcinoma: a case report and review of the literature
por: Urushibara, Masayasu, et al.
Publicado: (2022)

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
por: Larrinaga, Gorka, et al.
Publicado: (2021)

Anti-PD-1 Therapy-Associated Perforating Colitis
por: Celli, Romulo, et al.
Publicado: (2018)

PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
por: Leite, Katia R M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rhlopb2oimc5dvasp7fhil1omi